AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03722030 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mid-point Measures
Description: Accelerometer (steps)
Study NCT03722030 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Mid-point Measures
Description: Accelerometer (steps)
Study NCT03722030 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Post-Study Measures
Description: Accelerometer (steps), Biomarkers (finger prick for hemoglobin A1c and c-reactive protein), Anthropometrics (height, weight, waist and hip circumference), Body composition (dual-energy absorptiometry for measuring fat mass, lean mass, % body fat, visceral fat), Functional fitness test.
Study NCT03722030 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Post-Study Measures
Description: Accelerometer (steps), Biomarkers (finger prick for hemoglobin A1c and c-reactive protein), Anthropometrics (height, weight, waist and hip circumference), Body composition (dual-energy absorptiometry for measuring fat mass, lean mass, % body fat, visceral fat), Functional fitness test.
Study NCT03134638 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SY-1365 (Part 1)
Description: Two dosing schedules will be evaluated in dose escalation and a dose(s)/schedule(s) will be determined for Part 2:~* Twice weekly: SY-1365 will be administered by intravenous infusion over 1 or 2 hours twice a week for 3 weeks of each 4 week (28 day) cycle.~* Weekly: SY-1365 will be administered by intravenous infusion over 1 or 2 hours once a week for 3 weeks of each 4 week (28 day) cycle.
Study NCT03134638 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin will be administered on Day 1 of each 3 week (21-day) cycle (Part 2 only)
Study NCT03134638 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Fulvestrant will be administered as an intramuscular (IM) dose of 500 mg every 2 weeks for the first 3 doses on Day 1 and Day 15 of the first 28-day cycle (Cycle 1), and on Day 1 of the second 28 day cycle (Cycle 2), and monthly thereafter starting on Day 1 of Cycle 3 (Part 2 only)
Study NCT00367471 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carboplatin
Description: An alkylating agent used in the treatment of some cancers
Study NCT03134638 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SY-1365 (Cohort 2)
Description: In combination with carboplatin, SY-1365 will be administered by intravenous infusion over 1 or 2 hours for 2 weeks of each 3 week (21-day) cycle (Part 2 only)
Study NCT03134638 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SY-1365 (Cohort 5)
Description: In combination with fulvestrant, SY-1365 will be administered by intravenous infusion over 1 or 2 hours once a week for 3 weeks of each 4 week (28-day) cycle (Part 2 only)
Study NCT03134638 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SY-1365 (Part 2 Single Agent)
Description: SY-1365 will be administered by intravenous infusion over 1 or 2 hours twice a week for 3 weeks of each 4 week (28 day) cycle
Study NCT00367471 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: trastuzumab
Description: A monoclonal antibody that interferes with the HER2/neu receptor
Study NCT00367471 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel
Description: A mitotic inhibitor used in cancer treatment
Study NCT00715715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone Priming
Description: For randomly selected patients treated with steroids: The patients will receive prednisone 30 mg daily for 3 weeks, 15 mg daily for 1 week, no treatment for 2 weeks, followed by Adefovir dipivoxil (Hepsera) 10 mg daily for a minimum of 52 weeks.
Study NCT01674426 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy
Description: 16 sessions of 45 minutes each to review stress management
Study NCT01674426 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Cognitive behavior therapy
Description: 16 sessions of 45 minutes each to review stress management
Study NCT01736683 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotatercept
Description: Sotatercept is supplied as a lyophilized powder that is reconstituted using Water for Injection (WFI) and administered as a subcutaneous injection (SC) injection by the study staff at the clinical site.
Study NCT02817438 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Good Days Ahead
Description: Good Days Ahead is a web-based program based on the principles of Cognitive Behavioral Therapy (CBT). It can be used to supplement traditional psychotherapy, or as a stand-alone intervention. There are 9 lessons that address Thinking Skills, Behavioral Skills, Schemas, and Coping Tools. Lessons include videos from expert therapists and a Practice Section in which patients complete forms for self-monitoring symptoms and challenging negative thoughts.
Study NCT00827203 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elesclomol Sodium
Description: Chemotherapy agent
Study NCT04923373 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: telerehabilitation
Description: Procedure for both groups:~I pre surgery evaluation~1. initial training in hospital~2. physiotherapeutic programme telerehabilitation versus standard 7 times a week~Therapy duration: 6 weeks post-surgery II 6weeks post-surgery evaluation
Study NCT04923373 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: standard physiotherapy
Description: standard physiotherapy
Study NCT04265534 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telaglenastat
Description: Oral Glutaminase Inhibitor
Study NCT04265534 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Carboplatin Chemotherapy
Description: IV infusion
Study NCT04265534 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin Chemotherapy
Description: IV infusion
Study NCT04265534 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pemetrexed Chemotherapy
Description: IV infusion
Study NCT04265534 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed Chemotherapy
Description: IV infusion
Study NCT04265534 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Pembrolizumab Immunotherapy
Description: IV infusion
Study NCT04265534 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab Immunotherapy
Description: IV infusion
Study NCT04265534 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral placebo
Study NCT04265534 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Folic acid 400 -1000 μg
Description: Orally, once daily beginning 7 days prior to the first dose of pemetrexed and continue until 21 days after the last dose of pemetrexed.
Study NCT04265534 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Folic acid 400 -1000 μg
Description: Orally, once daily beginning 7 days prior to the first dose of pemetrexed and continue until 21 days after the last dose of pemetrexed.
Study NCT04265534 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin B12 1000 μg
Description: Vitamin B12 1000 μg Intramuscular injection one week prior to the first dose of pemetrexed and once every 3 cycles (9 weeks) thereafter. Subsequent vitamin B12 injections may be given the same day as pemetrexed administration.
Study NCT04265534 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin B12 1000 μg
Description: Vitamin B12 1000 μg Intramuscular injection one week prior to the first dose of pemetrexed and once every 3 cycles (9 weeks) thereafter. Subsequent vitamin B12 injections may be given the same day as pemetrexed administration.
Study NCT04265534 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexamethasone 4 mg
Description: For prophylaxis, orally twice per day (or equivalent). Taken the day before, day of, and day after pemetrexed administration.
Study NCT04265534 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone 4 mg
Description: For prophylaxis, orally twice per day (or equivalent). Taken the day before, day of, and day after pemetrexed administration.
Study NCT04369339 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Colposcopy
Study NCT04369339 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Colposcopy
Study NCT04055935 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: elevation of full thickness mucoperiosteal flap
Description: A free gingival sulcular incision was done from the distal surface of maxillary second premolar to the mesial side of the maxillary canine. A releasing oblique incision was done including the interdental papilla between maxillary canine and lateral incisor extending to the mucogingival junction just beyond the attached mucosa. The flap reflection extended beyond the canine root apex. A FTMPF reflection was done with mucoperiosteal elevator. Free sulcus incision was done to allow elevation of palatal mucosa by tunneling technique on the palatal gingiva of maxillary canine.
Study NCT00003766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: O6-benzylguanine
Study NCT02189226 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic submucosal dissection (ESD) with or without probe-based confocal laser endomicroscopy (pCLE)
Description: Before ESD, the lesion will be observed either by pCLE or by CE to determine proximal and distal margin of the lesion. In the pCLE group, after injection of intravenous fluorescein, the lesion will be observed using a flexible confocal miniprobe. In the CE group, the lesion will be observed conventionally under white light after spraying indigocarmine directly via the forceps channel. Marking dots will be placed on both margins using needle knife. Then several dots will be marked on the surrounding normal mucosa 5 mm from the tumor with Argon plasma coagulation. After injection of saline solution with epinephrine into the submucosa, an initial cut will be made with needle knife outside the line of surrounding marks. An insulation-tipped (IT) knife will be inserted into initial cut, and electrosurgical current will be applied to complete the incision around the tumor. After the circumferential cut, the submucosa will be dissected with the IT knife.
Study NCT02189226 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endoscopic submucosal dissection (ESD) with or without probe-based confocal laser endomicroscopy (pCLE)
Description: Before ESD, the lesion will be observed either by pCLE or by CE to determine proximal and distal margin of the lesion. In the pCLE group, after injection of intravenous fluorescein, the lesion will be observed using a flexible confocal miniprobe. In the CE group, the lesion will be observed conventionally under white light after spraying indigocarmine directly via the forceps channel. Marking dots will be placed on both margins using needle knife. Then several dots will be marked on the surrounding normal mucosa 5 mm from the tumor with Argon plasma coagulation. After injection of saline solution with epinephrine into the submucosa, an initial cut will be made with needle knife outside the line of surrounding marks. An insulation-tipped (IT) knife will be inserted into initial cut, and electrosurgical current will be applied to complete the incision around the tumor. After the circumferential cut, the submucosa will be dissected with the IT knife.
Study NCT04118335 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Black Mulberry Syrup
Description: The individuals in the intervention group gargled with 5 ml black mulberry syrup and waited average one minute and then swallow it.
Study NCT00374231 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus
Description: Tacrolimus is a pill taken orally. Dose, frequency and duration will be decided by the study doctor on a case-by-case basis.
Study NCT00374231 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil
Description: Mycophenolate mofetil is a pill taken orally. Dose, frequency and duration will be decided by the study doctor on a case-by-case basis.
Study NCT00374231 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone is a pill taken orally. Dose, frequency and duration will be decided by the study doctor on a case-by-case basis.
Study NCT01002963 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04418948
Description: solution, 30 mg, single
Study NCT01002963 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04418948
Description: solution, 100 mg, single
Study NCT01002963 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04418948
Description: solution, 300 mg, single
Study NCT01002963 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04418948
Description: solution, 1000 mg, single
Study NCT01002963 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04418948
Description: solution, 3000 mg, single
Study NCT01002963 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04418948
Description: solution, 4500 mg, single
Study NCT01002963 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04418948
Description: solution, 6000 mg, single
Study NCT00540995 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: busulfan
Description: Given IV
Study NCT00540995 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV
Study NCT00736476 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H.pylori vaccines
Description: 1 dose of H.pylori vaccine at 0, 1, and 2 months
Study NCT00736476 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Vaccine
Description: Placebo Vaccine at 0, 1, and 2 months
Study NCT01261377 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bi-level positive airway pressure (BPAP)
Description: The level of BPAP will be titrated to treat OSA as well as hypoxemia and hypercapnia. The duration of therapy will be six months.
Study NCT01261377 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen
Description: Oxygen will be titrated to keep resting oxygen saturation (as measured by pulse oximeter) more than 88 percent. The duration of therapy will be six months.
Study NCT01261377 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CPAP
Description: The level of CPAP will be titrated to treat OSA. The duration of therapy will be six months.
Study NCT00552500 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Depakote (valproate)
Description: 500 mg -2000 mg QD based on individual tolerance and VPA levels
Study NCT04055935 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: low level laser therapy
Description: LLLT was done using a diode soft laser (Epic X, BioLase, USA). It is a semiconductor diode soft laser. Active medium is In-Ga-As with 940nm wave length. LLLT protocol was using active laser tip (bleaching tip)
Study NCT02409498 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pudendal block
Description: preemptive pudendal nerve blockade with 10 ml of 0 .5 % Bupivacaine with epinephrine.
Study NCT00540995 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: intensity-modulated radiation therapy
Description: Initially 150 cGy X 8 doses with gradual dose escalation to 200 cGy X 10 doses
Study NCT00540995 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic hematopoietic stem cell transplantation
Description: Stem cell transplantation occurs on Day 0 after High Dose Therapy
Study NCT00540995 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic bone marrow transplantation
Description: Stem cell transplantation occurs on Day 0 after High Dose Therapy
Study NCT02409498 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: no pudendal block
Description: preemptive pudendal nerve blockade with 10 ml of normal saline to each side
Study NCT04354051 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Nitrite
Description: Intravenous nitrite sodium infusion, dose 70μmol, of 5 minute duration (14μmol /min-1).
Study NCT02412007 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Individualized comprehensive home centred activity based programme
Description: Simple activities would be advised on the basis of child's individual characteristics and parental expectations. These would include but would not be limited to~1. Standing up from squatting position to catch an object of interest.~2. Squatting from standing position to pick an object of interest.~3. Walking to reach an object of interest.~4. Climbing up steps to get an object of interest.~5. Climbing down steps to keep the above object of interest.~6. Cycling~7. Kicking a football~8. Dancing
Study NCT02412007 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Individualized comprehensive home centred activity based programme
Description: Simple activities would be advised on the basis of child's individual characteristics and parental expectations. These would include but would not be limited to~1. Standing up from squatting position to catch an object of interest.~2. Squatting from standing position to pick an object of interest.~3. Walking to reach an object of interest.~4. Climbing up steps to get an object of interest.~5. Climbing down steps to keep the above object of interest.~6. Cycling~7. Kicking a football~8. Dancing
Study NCT02383394 — intervention group
Intervention type: OTHER
Intervention: follow up antenatal care
Description: ultrasound follow up of pregnancy
Study NCT03905434 — intervention group
Intervention type: GENETIC
Intervention: miRNA sampling
Description: Blood samples for miRNA testing will be collected from all subjects (control and patients diagnosed with acute ischemic stroke)
Study NCT02127112 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Block Allograft plus Matrix Allograft
Description: A cancellous block allograft plus a demineralized bone matrix allograft will be used as the positive control treatment.
Study NCT02127112 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Moldable Matrix Allograft
Description: The test arm of this study will include a demineralized bone matrix allograft placed over resorbable bone pins.
Study NCT02127112 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Moldable Matrix Allograft
Description: The test arm of this study will include a demineralized bone matrix allograft placed over resorbable bone pins.
Study NCT00540995 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Description: Stem cell transplantation occurs on Day 0 after High Dose Therapy
Study NCT00540995 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: tomotherapy
Description: Initially 150 cGy X 8 doses with gradual dose escalation to 200 cGy X 10 doses
Study NCT00387933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydroxyurea
Study NCT00387933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imatinib mesylate
Study NCT00387933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vatalanib
Study NCT02380794 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Danshen Gegen Capsule
Description: Danshen can dilate blood vessels, reduce the number of angina attacks and significantly improve endothelial function in patients with Coronary Angina Pectoris.~Gegen is also effective in dilating cardiovascular and cerebrovascular of the brain, and improving blood circulation. The main active ingredient of Gegen isoflavones is effective in dilating the coronary arteries, improving metabolism in normal and ischemic myocardium and reducing blood pressure, heart rate and myocardial oxygen consumption.
Study NCT02380794 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03958396 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil Infusion
Description: 15 minute remifentanil Infusion of either 0.05, 0.1, 0.15 or 0.2 mcg/kg/min
Study NCT02538627 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MM-151
Description: MM-151
Study NCT02538627 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MM-121
Description: MM-121
Study NCT02538627 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MM-141
Description: MM-141
Study NCT02538627 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trametinib
Description: trametininb
Study NCT04113486 — intervention group
Intervention type: OTHER
Intervention: Blood test
Description: About 4 ml of blood draw
Study NCT02530073 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fetoscopic Endoluminal Tracheal Occlusion (FETO)
Description: This study will position and remove an endoluminal tracheal balloon in utero (FETO) to study the feasibility of implementing FETO therapy in the most severe group of fetuses with left CDH and observed/expected length head ratio \<25% (O/E LHR).
Study NCT02829957 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apixaban
Description: 10mg BID for 7 days, then 5mg BID for three months
Study NCT03704662 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Stereotactic Body Radiation Therapy
Description: Undergo SBRT
Study NCT04776941 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT04776941 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies